Oruka Therapeutics (ORKA)

• Market cap: $3.71B
• 1 day: -3.08%
• 5 days: -4.83%
• 1 month: -5.52%
• 3 months: 89.5%
• 6 months: 119.38%
• Year to date: 119.07%
• 1 year: 554.65%
• 5 years: 57.34%
• 10 years: -91.54%
• Sector: Healthcare
• Industry: Biotechnology

About: Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Employees: 68